TORONTO and WINNIPEG, Aug. 29 /CNW/ - Cangene Corporation today reports that it has completed delivery of the initial order for anthrax immune globulin and the drug has been formally received into the U.S. Strategic National Stockpile (“SNS”). This acceptance of product into the SNS by the U.S. Department of Health and Human Services (managed by the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) within HHS) confirms that Cangene can proceed to invoice for approximately one third of the previously disclosed $US18-22 million total; the remainder will be invoiced shortly, when delivery of the botulism toxin immune globulin has similarly been completed.
